Skip to main content
SpringerLink
Log in

Clopidogrel

A Pharmacoeconomic Review of its Use in Patients with Non-ST Elevation Acute Coronary Syndromes

  • Adis Pharmacoeconomic Drug Evaluation
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Clopidogrel (Plavix®) is a selective inhibitor of adenosine diphosphate-induced platelet aggregation. In patients with acute coronary syndromes (ACS) [unstable angina or non-ST-segment elevation myocardial infarction], clopidogrel plus aspirin (acetylsalicylic acid) for up to 1 year significantly reduced the risk of cardiovascular events relative to placebo plus aspirin in the well designed clinical trial CURE (Clopidogrel in Unstable angina to prevent Recurrent Events) and its substudy in patients undergoing percutaneous coronary intervention (PCI) [PCI-CURE].

In pharmacoeconomic evaluations based on data from these trials conducted in a number of countries that used a variety of models, methods and/or type of costs, clopidogrel plus aspirin was consistently predicted to be cost effective relative to aspirin alone in the management of patients with ACS, including those undergoing PCI.

Clopidogrel plus aspirin in patients with ACS reduced the incremental cost per cardiovascular event prevented and/or life-year gained (LYG) relative to aspirin alone in analyses using within-trial data (including longer-term analyses incorporating life-expectancy estimates) from the CURE or PCI-CURE studies. In Markov models of cost effectiveness with a lifetime horizon from a healthcare payer perspective based on the CURE trial, relative to aspirin alone, clopidogrel plus aspirin for 1 year was predicted to have incremental costs per LYG of €8132 in Spain (2003 values) and €1365 in Sweden (2000 values). In similar Swedish analyses from a healthcare payer perspective, clopidogrel plus aspirin for 1 year was predicted to have incremental costs per LYG of €10 993 (2004 values) relative to aspirin alone based on data from the PCI-CURE substudy. Broadly similar results have also been reported in modelled analyses from other countries. Cost-utility analyses based on the CURE trial suggest that, relative to lifelong aspirin alone, clopidogrel plus aspirin for 1 year followed by aspirin alone is associated with incremental costs per QALY gained that are below the traditional threshold of cost utility in Spain, the UK and the US.

In patients with ACS, including those undergoing PCI, the addition of clopidogrel to standard therapy with aspirin is clinically effective in preventing cardiovascular events. Available pharmacoeconomic data from several countries, despite some inherent limitations, support the use of clopidogrel plus aspirin for up to 1 year as a cost-effective treatment relative to aspirin alone in this patient population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V
Table VI

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina) [online]. Available from URL: http://www.acc.org [Accessed 2006 Apr 11]

  2. National Institute for Clinical Excellence. Clopidogrel in the treatment of non-ST-segment elevation acute coronary syndrome: technology appraisal 80 [online]. Available from URL: http://www.nice.org.uk [Accessed 2006 Apr 11]

  3. Fox KAA, Cokkinos DV, Deckers J, etal. The ENACT study: a pan-European survey of acute coronary syndromes. Eur Heart J 2000 Sep; 21 (17): 1440–1449

    Article  PubMed  CAS  Google Scholar 

  4. Brieger D, Eagle KA, Goodman SG, et al. Acute coronary syndromes without chest pain, an underdiagnosed and under-treated high-risk group: insights from the Global Registry of Acute Coronary Events. Chest 2004 Aug; 126 (2): 461–469

    Article  PubMed  Google Scholar 

  5. Taneja AK, Collinson J, Flather M, et al. Mortality following non-ST elevation acute coronary syndrome: 4 years follow-up of the PRAIS UK Registry (Prospective Registry of Acute Ischaemic Syndromes in the UK). Eur Heart J 2004; 25: 2013–2018

    Article  PubMed  Google Scholar 

  6. Easthope SE, Jarvis B. Clopidogrel: potential in the prevention of cardiovascular events in patients with acute coronary syndromes. Am J Cardiovasc Drugs 2001; 1 (6): 467–474; discussion 475-6

    Article  PubMed  CAS  Google Scholar 

  7. Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership. Plavix (clopidogrel bisulfate tablets): prescribing information. 2004 Nov

    Google Scholar 

  8. Bertrand ME, Simoons ML, Fox KAA, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002 Dec; 23 (23): 1809–1840

    Article  PubMed  Google Scholar 

  9. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005 Mar 24; 352 (12): 1179–1189

    Article  PubMed  CAS  Google Scholar 

  10. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005 Nov 5; 366 (9497): 1607–1621

    Article  Google Scholar 

  11. Steinhubl SR, Berger PB, Mann III JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002 Nov 20; 288: 2411–2420

    Article  PubMed  CAS  Google Scholar 

  12. Patel MR, Roe MT. Pharmacological treatment of elderly patients with acute coronary syndromes without persistent ST segment elevation. Drugs Aging 2002; 19 (9): 633–646

    Article  PubMed  CAS  Google Scholar 

  13. Rosengren A, Wallentin L, Gitt AK, et al. Sex, age, and clinical presentation of acute coronary syndromes. Eur Heart J 2004 Apr; 25 (8): 663–670

    Article  PubMed  Google Scholar 

  14. American Heart Association. Heart disease and stroke statistics: 2006 update [online]. Available from URL: http://www.americanheartassociation.com [Accessed 2006 Apr 18]

  15. Walsh SJ, Spence MS, Crossman D, et al. Clopidogrel in non-ST segment elevation acute coronary syndromes: an overview of the submission by the British Cardiac Society and the Royal College of Physicians of London to the National Institute for Clinical Excellence, and beyond. Heart 2005; 91 (9): 1135–1140

    Article  PubMed  CAS  Google Scholar 

  16. Hare DL, Silverton M. Recovery from acute coronary syndromes: hidden snares to resuming normality. Aust Fam Physician 2001 Oct; 30 (10): 959–963

    PubMed  CAS  Google Scholar 

  17. Clopidogrel in Unstable angina to prevent Recurrent Events trial investigators (CURE). Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494–502

    Article  Google Scholar 

  18. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358 (9281): 527–533

    Article  PubMed  CAS  Google Scholar 

  19. Peters RJG, Mehta SR, Fox KAA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003 Oct 7; 108 (14): 1682–1687

    Article  PubMed  CAS  Google Scholar 

  20. Fox KAA, Mehta SR, Peters R, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) trial. Circulation 2004 Sep 7; 110 (10): 1202–1208

    Article  PubMed  CAS  Google Scholar 

  21. Budaj A, Yusuf S, Mehta SR, et al. Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. Circulation 2002 Sep 24; 106: 1622–1626

    Article  PubMed  Google Scholar 

  22. Lewis BS, Mehta SR, Fox KA, et al. Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Am Heart J 2005 Dec; 150 (6): 1177–1184

    Article  PubMed  CAS  Google Scholar 

  23. Annemans L, Lindgren P, Frei A, et al. Cost-effectiveness analysis of clopidogrel in acute coronary syndromes without ST-segment elevation: a five European countries analysis [abstract no. P3002]. Eur Heart J 2003 Aug–Sep; 24 Abstr. Suppl.: 586

    Article  Google Scholar 

  24. Belousov YE, Lazebnik LB, Bykov AV, et al. Economic analysis of the use of clopidogrel in patients with acute coronary syndrome without ST-segment elevation from the Russian health care system perspective [abstract no. PCV52]. Value Health 2003 Nov–Dec; 6 (6): 663

    Article  Google Scholar 

  25. Lamy A, Jonsson B, Weintraub WS, et al. The cost-effectiveness of the use of clopidogrel in acute coronary syndromes in five countries based upon the CURE study. Eur J Cardiovasc Prev Rehabil 2004 Dec; 11 (6): 460–465

    Article  PubMed  Google Scholar 

  26. Pietrasik A, Niewada M, Spiesser J, et al. The cost-effectiveness of clopidogrel in acute coronary syndromes without ST-segment elevation in Poland [abstract no. PCV7]. Value Health 2004 Nov–Dec; 7 (6): 687. Plus poster presented at the 7th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research; 2004 Oct 24–26; Hamburg

    Google Scholar 

  27. Mehta SR, Weintraub WS, Jonsson B, et al. Incremental cost-effectiveness of early and long-term clopidogrel in patients undergoing percutaneous coronary infarction in the CURE trial: the PCI-CURE economic analysis [abstract no. 1171-112]. J Am Coll Cardiol 2003 Mar 19; 41 (6 Suppl. A): 383A. Plus poster presented at the 52nd Annual Scientific Sesson of the American College of Cardiology; 2003 Mar 30–Apr 2; Chicago (IL)

    Article  Google Scholar 

  28. Spiesser J, Carita P, Annemans L, et al. Economic impact of clopidogrel in patients with acute coronary syndromes without ST-segment elevation undergoing percutaneous coronary interventions: a European overview [abstract no. PCV23]. Value Health 2003 Nov–Dec 31; 6 (6): 651. Plus poster presented at the 6th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research; 2003 Nov 9–11; Barcelona

    Article  Google Scholar 

  29. Weintraub WS, Mahoney EM, Lamy A, et al. Long-term costeffectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. J Am Coll Cardiol 2005 Mar 15; 45 (6): 838–845

    Article  PubMed  CAS  Google Scholar 

  30. Mahoney EM, Mehta S, Yuan Y, et al. Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation. Am Heart J 2006 Jan; 151 (1): 219–227

    Article  PubMed  CAS  Google Scholar 

  31. Frei A, Lindgren P, Meier B. Cost-effectiveness of clopidogrel in patients with acute coronary syndrome in Switzerland. Kardiovask Med 2004; 7: 174–180

    Google Scholar 

  32. Badia X, Bueno H, Gonzalez Juanatey JR, et al. Short- and long-term cost-effectiveness analysis of adding clopidogrel to standard therapy in acute coronary syndrome patients in Spain. Rev Esp Cardiol 2005 Dec; 58 (12): 1385–1395

    Article  PubMed  Google Scholar 

  33. Lindgren P, Jonsson B, Yusuf S. Cost-effectiveness of clopidogrel in acute coronary syndromes in Sweden: a long-term model based on the CURE trial. J Intern Med 2004 May; 255 (5), 562–570

    Article  CAS  Google Scholar 

  34. Lindgren P, Stenestrand U, Malrmerg K, et al. The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden. Clin Ther 2005 Jan; 27 (1): 100–110

    Article  PubMed  CAS  Google Scholar 

  35. Bruggenjurgen B, Ehlken B. Long-term cost-effectiveness of Clopidogrel® in patients with acute coronary syndrome without ST-segment elevation in Germany [abstract no. PCV5]. Value Health 2004 Nov–Dec; 7 (6): 686. Plus poster presented at the 7th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research; 2004 Oct 24–26; Hamburg

    Article  Google Scholar 

  36. van Hout BA, Tangelder MID, Bervoets P, et al. Cost-effectiveness analysis of clopidogrel in acute coronary syndromes without ST-segment elevation in the Netherlands [abstract no. PCV63]. Value Health 2003 Nov–Dec; 6 (6): 667–866

    Article  Google Scholar 

  37. Ko S, Park D, Yang BM. Cost-effectiveness analysis of clopidogrel in acute coronary syndromes in South Korea based on CURE trial [abstract no. PCV1]. 2nd Asia-Pacific International Society for Pharmacoeconomics and Outcomes Research Conference; 2006 Mar 5–7; Shanghai

  38. Tarn TH. Long-term cost-effectiveness of clopidogrel in acute coronary syndromes: CURE model Taiwan adaptation [abstract no. CV4]. 2nd Asia-Pacific International Society for Pharmacoeconomics and Outcomes Research Conference; 2006 Mar 5–7; Shanghai

  39. Lindgren P, Jonsson B, Spiesser J, et al. Short and long term cost-effectiveness analysis of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Scandinavian countries [abstract no. CV5]. Value Health 2003 Nov–Dec; 6 (6): 621

    Article  Google Scholar 

  40. Karnon J, Bakhai A, Brennan A, et al. A cost-utility analysis of clopidogrel in patients with non-ST-segment-elevation acute coronary syndromes in the UK. Int J Cardiol 2006 May 24; 109 (3), 307–316

    Article  PubMed  CAS  Google Scholar 

  41. Latour-Perez J, Navarro-Ruiz A, Ridao-Lopez M, et al. Using clopidogrel in non-ST-segment elevation acute coronary syndrome patients: a cost-utility analysis in Spain. Value Health 2004 Jan; 7 (1): 52–60

    Article  PubMed  Google Scholar 

  42. Main C, Palmer S, Griffin S, et al. Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation. Health Technol Assess 2004 Oct; 8 (40)

    Google Scholar 

  43. Schleinitz MD, Heidenreich PA. A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. Ann Intern Med 2005 Feb 15; 142 (4): 251–259

    PubMed  CAS  Google Scholar 

  44. Hordijk-Trion M, Lenzen M, Wijns W, et al. Patients enrolled in coronary intervention trials are not representative of patients in clinical practice: results from the Euro Heart Survey on Coronary Revascularization. Eur Heart J 2006; 27: 671–678

    Article  PubMed  Google Scholar 

  45. Fox KAA, Goodman SG, Klein W, et al. Management of acute coronary syndromes: variations in practice and outcome. Findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002; 23 (15): 1177–1189

    Article  PubMed  CAS  Google Scholar 

  46. Krurmolz HM, Pasternak RC, Weinstein Me, et al. Cost effectiveness of throrrbolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction. N Engl J Med 1992 Jul 2; 327 (1): 7–13

    Article  Google Scholar 

  47. Johannesson M, Jonsson B, Kjekshus J, et al. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease: Scandinavian Simvastatin Survival Study Group. N EngI J Med 1997 Jan 30; 336 (5): 332–336

    Article  CAS  Google Scholar 

  48. Tsevat J, Kuntz KM, Oray EJ, et al. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels. Am Heart J 2001 May; 141 (5): 727–734

    Article  PubMed  CAS  Google Scholar 

  49. Mark D, Harrington R, Lincoff A, et al. Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. Circulation 2000 Feb 1; 101 (4): 366–371

    Article  PubMed  CAS  Google Scholar 

  50. Mahoney EM, Jurkovitz Cf, Chu H, et al. Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatrrent of unstable angina and non-ST-segment elevation myocardial infarction. JAMA 2002 Oct 16; 288 (15): 1851–1858

    Article  PubMed  Google Scholar 

  51. Phillips KA, Shlipak MG, Coxson P, et al. Health and economic benefits of increased l3-blocker use following myocardial infarction. JAMA 2000 Dec 6; 284 (21): 2748–2754

    Article  PubMed  CAS  Google Scholar 

  52. Serebruany VL, Steinhubl SR, Berger PB, et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005 Jan 18; 45 (2): 246–251

    Article  PubMed  CAS  Google Scholar 

  53. Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioseler Throrm Vase Biol 2004; 24 (11): 1980–1987

    Article  CAS  Google Scholar 

  54. Moseucci M, Fox KAA, Cannon CP, et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003 Oct; 24 (20): 1815–1823

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 1311, New Zealand

    Katherine A. Lyseng-Williamson & Greg L. Plosker

Authors
  1. Katherine A. Lyseng-Williamson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Greg L. Plosker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katherine A. Lyseng-Williamson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lyseng-Williamson, K.A., Plosker, G.L. Clopidogrel. Pharmacoeconomics 24, 709–726 (2006). https://doi.org/10.2165/00019053-200624070-00009

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200624070-00009

Keywords

Search

Navigation